{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T13:09:50Z","timestamp":1781788190471,"version":"3.54.5"},"reference-count":20,"publisher":"American Society for Microbiology","issue":"4","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100007819","name":"Allergan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2017,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Bacterial isolates were collected from patients hospitalized with pneumonia (PHP), including ventilator-associated pneumonia (VAP), from 76 U.S. medical centers in 2011 to 2015. The Gram-negative organisms (\n            <jats:italic>n<\/jats:italic>\n            = 11,185, including 1,097 from VAP) were tested for susceptibility to ceftazidime-avibactam and comparators by the broth microdilution method. \u03b2-Lactamase-encoding genes were screened using a microarray-based assay on selected isolates.\n            <jats:named-content content-type=\"genus-species\">Pseudomonas aeruginosa<\/jats:named-content>\n            and\n            <jats:named-content content-type=\"genus-species\">Klebsiella<\/jats:named-content>\n            spp. were the most common Gram-negative bacteria isolated from PHP and VAP. Ceftazidime-avibactam was very active against\n            <jats:named-content content-type=\"genus-species\">P. aeruginosa<\/jats:named-content>\n            (\n            <jats:italic>n<\/jats:italic>\n            = 3,402; MIC\n            <jats:sub>50<\/jats:sub>\n            \/MIC\n            <jats:sub>90<\/jats:sub>\n            , 2 and 4 \u03bcg\/ml; 96.6% susceptible), including isolates nonsusceptible to meropenem (86.3% susceptible to ceftazidime-avibactam), piperacillin-tazobactam (85.6% susceptible), or ceftazidime (80.6% susceptible). Ceftazidime-avibactam was also highly active against\n            <jats:named-content content-type=\"genus-species\">Enterobacteriaceae<\/jats:named-content>\n            (MIC\n            <jats:sub>50<\/jats:sub>\n            \/MIC\n            <jats:sub>90<\/jats:sub>\n            , 0.12 and 0.5 \u03bcg\/ml; 99.9% susceptible), including carbapenem-resistant\n            <jats:named-content content-type=\"genus-species\">Enterobacteriaceae<\/jats:named-content>\n            (CRE) (\n            <jats:italic>n<\/jats:italic>\n            = 189; MIC\n            <jats:sub>50<\/jats:sub>\n            \/MIC\n            <jats:sub>90<\/jats:sub>\n            , 0.5 and 2 \u03bcg\/ml; 98.0% susceptible) and multidrug-resistant (MDR) (\n            <jats:italic>n<\/jats:italic>\n            = 674; MIC\n            <jats:sub>50<\/jats:sub>\n            \/MIC\n            <jats:sub>90<\/jats:sub>\n            , 0.25 and 1 \u03bcg\/ml; 98.8% susceptible) and extensively drug-resistant (XDR) (\n            <jats:italic>n<\/jats:italic>\n            = 156; MIC\n            <jats:sub>50<\/jats:sub>\n            \/MIC\n            <jats:sub>90<\/jats:sub>\n            , 0.5 and 2 \u03bcg\/ml; 98.1% susceptible)\n            <jats:named-content content-type=\"genus-species\">Enterobacteriaceae<\/jats:named-content>\n            isolates, as well as\n            <jats:named-content content-type=\"genus-species\">Klebsiella<\/jats:named-content>\n            species isolates showing an extended-spectrum \u03b2-lactamase (ESBL) screening-positive phenotype (\n            <jats:italic>n<\/jats:italic>\n            = 433; MIC\n            <jats:sub>50<\/jats:sub>\n            \/MIC\n            <jats:sub>90<\/jats:sub>\n            , 0.25 and 1 \u03bcg\/ml; 99.5% susceptible). Among\n            <jats:named-content content-type=\"genus-species\">Enterobacter<\/jats:named-content>\n            spp. (24.8% ceftazidime nonsusceptible), 99.8% of the isolates, including 99.4% of ceftazidime-nonsusceptible isolates, were susceptible to ceftazidime-avibactam. The most common \u03b2-lactamases detected among\n            <jats:named-content content-type=\"genus-species\">Klebsiella pneumoniae<\/jats:named-content>\n            and\n            <jats:named-content content-type=\"genus-species\">E. coli<\/jats:named-content>\n            isolates were\n            <jats:named-content content-type=\"genus-species\">K. pneumoniae<\/jats:named-content>\n            carbapenemase (KPC)-like and CTX-M-15, respectively. Only 8 of 6,209\n            <jats:named-content content-type=\"genus-species\">Enterobacteriaceae<\/jats:named-content>\n            isolates (0.1%) were ceftazidime-avibactam nonsusceptible, three NDM-1-producing strains with ceftazidime-avibactam MIC values of &gt;32 \u03bcg\/ml and five isolates with ceftazidime-avibactam MIC values of 16 \u03bcg\/ml and negative results for all \u03b2-lactamases tested. Susceptibility rates among isolates from VAP were generally similar or slightly higher than those from all PHP.\n          <\/jats:p>","DOI":"10.1128\/aac.02083-16","type":"journal-article","created":{"date-parts":[[2017,1,10]],"date-time":"2017-01-10T02:30:27Z","timestamp":1484015427000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":52,"title":["Antimicrobial Activity of Ceftazidime-Avibactam against Gram-Negative Bacteria Isolated from Patients Hospitalized with Pneumonia in U.S. Medical Centers, 2011 to 2015"],"prefix":"10.1128","volume":"61","author":[{"given":"Helio S.","family":"Sader","sequence":"first","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Castanheira","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert K.","family":"Flamm","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1177\/0885066610371189"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw504"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S25985"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2014.01.007"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04839-14"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1086\/668770"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp197"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2015.08.011"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-013-0013-7"},{"key":"e_1_3_2_11_2","volume-title":"Avycaz (ceftazidime-avibactam) package insert","author":"FDA","year":"2015","unstructured":"FDA. 2015. Avycaz (ceftazidime-avibactam) package insert. FDA, Washington, DC. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/206494s000lbl.pdf. Accessed March 2016."},{"key":"e_1_3_2_12_2","unstructured":"AstraZeneca\nAB\n. 2016. Zavicefta package insert. European Medicines Agency London United Kingdom. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/004027\/WC500210234.pdf\n. Accessed September 2016."},{"key":"e_1_3_2_13_2","first-page":"108","article-title":"Notes from the field: hospital outbreak of carbapenem-resistant Klebsiella pneumoniae producing New Delhi metallo-beta-lactamase\u2014Denver, Colorado, 2012","volume":"62","author":"Centers for Disease Control and Prevention","year":"2013","unstructured":"Centers for Disease Control and Prevention. 2013. Notes from the field: hospital outbreak of carbapenem-resistant Klebsiella pneumoniae producing New Delhi metallo-beta-lactamase\u2014Denver, Colorado, 2012. MMWR Morb Mortal Wkly Rep62:108.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu219"},{"key":"e_1_3_2_15_2","unstructured":"EUCAST. 2017. Breakpoint tables for interpretation of MICs and zone diameters version 7.0 January 2017. http:\/\/www.eucast.org\/clinical_breakpoints\/. Accessed January 2017."},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02436-12"},{"key":"e_1_3_2_17_2","volume-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard","author":"Clinical and Laboratory Standards Institute","year":"2015","unstructured":"Clinical and Laboratory Standards Institute. 2015. M07-A10. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 10th ed. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"10"},{"key":"e_1_3_2_18_2","volume-title":"Performance standards for antimicrobial susceptibility testing: 26th informational supplement","author":"Clinical and Laboratory Standards Institute","year":"2016","unstructured":"Clinical and Laboratory Standards Institute. 2016. M100-S26. Performance standards for antimicrobial susceptibility testing: 26th informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2011.03570.x"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00540-16"},{"key":"e_1_3_2_21_2","volume-title":"Tygacil package insert","author":"Wyeth Pharmaceuticals, Inc","year":"2015","unstructured":"Wyeth Pharmaceuticals, Inc. 2015. Tygacil package insert. Wyeth Pharmaceuticals, Inc., Madison, NJ. http:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=491. Accessed August 2015."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02083-16","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02083-16","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T20:50:58Z","timestamp":1645476658000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02083-16"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["10.1128\/AAC.02083-16"],"URL":"https:\/\/doi.org\/10.1128\/aac.02083-16","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"2016-09-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-12-26","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-03-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e02083-16"}}